Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06665373 · ClinicalTrials.gov registry record · NA

Fitness and Nutrition in Glioma

A NA study of Malignant Glioma, sponsored by NYU Langone Health.

Recruiting
Registry status
NA
Development phase
15
Enrollment target
1
Study location

NCT06665373 is a NA study of Malignant Glioma that is actively recruiting participants, run by NYU Langone Health. The registered enrollment target is 15 participants, below the 92-participant average among 40 other Malignant Glioma trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06665373, a NA study of Malignant Glioma, is actively recruiting participants, sponsored by NYU Langone Health.

RECRUITING
Registry status
NA
Development phase
15 participants
Enrollment target
1
Study location

Study Summary

This is a pilot study assessing the effects of combining a modified Atkins diet with a physical fitness regimen in patients with malignant glioma. A sample size of 15 participants will be enrolled in a 15-week program consisting of two weekly supervised exercise sessions combined with an individualized home exercise program and a modified Atkins diet.

Conditions Studied

Interventions

  • BEHAVIORAL Modified Atkins Diet
  • BEHAVIORAL Fitness Program

Study Locations (1)

New York

  • NYU Langone Health - New York

Trial Details

FieldValue
Enrollment Target 15 participants
Start Date 2024-10-01
Est. Completion 2026-10
Phase NA

Sponsor

NYU Langone Health

1,164 total trials

What the Registry Record Tells You About NCT06665373

The ClinicalTrials.gov registry entry for NCT06665373 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 92-participant average among 40 other Malignant Glioma trials with a reported enrollment target (84% lower). The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Malignant Glioma appearing as the primary indexed condition, and to 2 interventions - of which Modified Atkins Diet is the first listed.

NCT06665373 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT06665373 about?

NCT06665373 is a clinical study titled "Fitness and Nutrition in Glioma". This is a pilot study assessing the effects of combining a modified Atkins diet with a physical fitness regimen in patients with malignant glioma. A sample size of 15 participants will be enrolled in a 15-week program consisting of two weekly supervised exercise sessions combined with an individuali...

What is the current status of trial NCT06665373?

This trial is currently recruiting. It is a NA study. The enrollment target is 15 participants. The study started on 2024-10-01. Estimated completion is 2026-10.

What conditions does trial NCT06665373 study?

This clinical trial studies the following conditions: Malignant Glioma.

What interventions are being tested in trial NCT06665373?

The interventions under investigation include: Modified Atkins Diet (BEHAVIORAL), Fitness Program (BEHAVIORAL).

Who is sponsoring clinical trial NCT06665373?

This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06665373 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Malignant Glioma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.